Does Cosentyx Reduce COVID-19 Vaccine Effectiveness?
Cosentyx (secukinumab), an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can blunt antibody responses to COVID-19 vaccines, particularly mRNA types like Pfizer-BioNTech or Moderna. Studies show patients on secukinumab produce fewer neutralizing antibodies after two doses compared to healthy controls, though T-cell responses often remain intact.[1][2]
A 2022 study in Rheumatology found secukinumab users had 50-70% lower anti-spike IgG levels post-vaccination versus non-immunosuppressed groups, with similar trends for boosters.[3] Real-world data from psoriasis patients confirms weaker humoral immunity, but breakthrough infections occur at rates comparable to the general population when vaccinated.[4]
How Does It Compare to Other Biologics?
Secentyx impacts vaccine response less severely than TNF inhibitors (e.g., adalimumab) or JAK inhibitors, where antibody levels drop over 80% in some cases. IL-17 blockers like secukinumab preserve more T-cell function, potentially offering hybrid protection against severe COVID-19.[2][5] B-cell depleters like rituximab show the weakest responses overall.
| Biologic Class | Typical Antibody Reduction | T-Cell Impact |
|---------------|----------------------------|--------------|
| IL-17 inhibitors (Cosentyx) | 50-70% | Minimal |
| TNF inhibitors | 60-85% | Moderate |
| JAK inhibitors | 70-90% | Variable |
| B-cell depleters | >90% | Severe |
What Do Guidelines Recommend?
Rheumatology societies (ACR, EULAR) advise continuing Cosentyx without interruption around vaccination, as stopping increases disease flare risk without clear efficacy gains. Boosters are prioritized for these patients due to partial protection.[6][7] CDC notes immunosuppressed individuals may need additional doses or serologic testing to confirm response.
Can You Test Vaccine Response on Cosentyx?
Yes, antibody titer tests (e.g., anti-spike IgG) gauge individual response 2-4 weeks post-vaccination. Low levels (<100 BAU/mL) suggest poor protection, prompting extra doses or antivirals like Paxlovid for high-risk exposure.[8] T-cell assays exist but are less available.
Does It Increase COVID-19 Severity?
No strong evidence links Cosentyx to worse outcomes. Vaccinated patients on IL-17 inhibitors had hospitalization rates similar to controls in large cohorts, thanks to preserved innate immunity.[4][9] Unvaccinated or non-responders face higher risks, as with any immunosuppressant.
Timing and Booster Strategies
Vaccinate during Cosentyx troughs if possible (end of dosing interval), but data shows minimal difference. Boosters restore antibodies better than primaries in these patients—aim for 4-6 months post-primary series.3
Sources
[1]: https://pubmed.ncbi.nlm.nih.gov/35171225/ (JAMA Dermatol, 2022)
[2]: https://pubmed.ncbi.nlm.nih.gov/34370811/ (Ann Rheum Dis, 2021)
[3]: https://academic.oup.com/rheumatology/article/61/10/4024/6574960 (Rheumatology, 2022)
[4]: https://pubmed.ncbi.nlm.nih.gov/35766894/ (Br J Dermatol, 2022)
[5]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801394/ (Vaccines, 2022)
[6]: https://rheumatology.org/covid-19-vaccine-clinical-guidance
[7]: https://ard.bmj.com/content/81/5/606 (Ann Rheum Dis, EULAR 2022)
[8]: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/immunocompromised.html
[9]: https://pubmed.ncbi.nlm.nih.gov/35866469/ (Lancet Rheumatol, 2022)